Artax Biopharma has appointed Joseph Lobacki as its new chief executive officer. Lobacki’s prior experience includes roles at Sanofi Genzyme, Medivation, Verastem (NASDAQ: VSTM), and Micromet, which was later acquired by Amgen (NASDAQ: AMGN). He succeeds company co-founder Damia Tormo, who has served as Artax’s CEO since its 2013 founding. The company says Tormo will remain on the board of directors.
Cambridge, MA-based Artax is preparing to move its lead drug candidate, AX-158, into the clinic to evaluate it as a treatment for multiple autoimmune diseases. The small molecule drug is designed to address such conditions without causing immunosuppression.